Friday, February 26, 2021

Opinion Today: Which Covid vaccine should you get?

More are coming soon.

By Alexandra Sifferlin

Senior Staff Editor

There will likely be a third Covid-19 vaccine approved for use in the United States very soon.

Today, a committee of experts for the Food and Drug Administration is reviewing Johnson & Johnson's one-dose Covid-19 vaccine to decide whether it should be granted "emergency use authorization" — the green light that would allow it to be put into arms across the country. The clinical trial data shows the vaccine is safe and can strongly protect against severe Covid-19 and death, so it's expected to get approval.

As the new health and science editor for Opinion, my question when covering the pandemic is always: What does this mean for the average person?

Experts have said for months that people should get any of the F.D.A.-approved vaccines. But it's helpful to understand why.

The effectiveness data for the Johnson & Johnson vaccine looks great compared to any reasonable benchmark for a vaccine against the coronavirus, even if the numbers are not quite as good as those reported by Pfizer-BioNTech and Moderna.

It's understandable for people to wonder if they should try to hold out for what they may think is the "better" vaccine. In anticipation of these questions — and, honestly, to address the many DMs and texts I receive from readers and friends about this — I asked Dr. Bruce Y. Lee, the executive director of the public health research group PHICOR, to share the reasons people should get whatever vaccine they can the fastest, based on his published research.

ADVERTISEMENT

As Lee details in his Op-Ed today, his team developed a computational simulation model of the entire United States and assessed what would happen if people got vaccines of varying levels of efficacy at different rates and times. "As we reported in The American Journal of Preventive Medicine, in most cases, getting people vaccinated sooner with a lower efficacy vaccine prevented many more Covid-19 cases, hospitalizations and deaths compared to waiting even just a month for a higher efficacy vaccine," Lee writes.

He also argues that there are other factors beyond effectiveness rates that make a vaccine worthwhile. The Johnson & Johnson vaccine only requires one dose and can be stored at regular refrigerator temperatures. The Pfizer-BioNTech and Moderna vaccines need to be stored in freezing temperatures and require people to receive two shots, separated by a few weeks.

I always hesitate to use the words "game changer," so let's just say the expected approval of the Johnson & Johnson vaccine has the potential to greatly improve vaccine rollout in the United States and the rest of the world.

And as Lee writes, getting any of the approved vaccines as soon as you are eligible is important — "not just for protecting yourself, but for helping get life back to normal for everyone."

ADVERTISEMENT

Here's what we're focusing on today:

On Politics

Mitch McConnell Doesn't Get to Define 'Bipartisan'

If 70 percent of Americans support a policy, including most Republicans, it is bipartisan — regardless of what some senators think about it.

By Michelle Cottle

Article Image

The Paradox of Pandemic Partisanship

Many Republicans consider Biden illegitimate — and support his plans.

By Paul Krugman

Article Image

The South Is More Than Its Shading on an Electoral Map

As the Amazon unionization drive reminds us, the region is home to a rich history of resistance.

By Jamelle Bouie

Article Image

The Campaign to Cancel Wokeness

How the right is trying to censor critical race theory.

By Michelle Goldberg

Article Image

What's 'Southern Hospitality' Without a Living Wage?

In Georgia, low-wage service sector workers and their employers are wrestling with the details, and the morality, of a $15 minimum wage.

By Ariel Felton

Article Image

ADVERTISEMENT

Ideas

How We Can Better Predict Weather Catastrophes

We need to develop an early warning system to forecast climate-induced extreme weather events.

By Abhishek Chatterjee, William Collins, David Crisp and Arun Majumdar

Article Image

How to Get Really Rich!

Getting into the right job is the key.

By David Brooks

Article Image

The Case for, and Against, Climate Optimism

Will the crisis in Texas become the new normal? David Wallace-Wells and Leah Stokes discuss.

By Ezra Klein

Article Image

A Sacred Place Undone by Trump Must Be Saved by Biden

Bears Ears is one of the nation's most compelling and mysterious landscapes and a place of worship for Native Americans.

By David Roberts

Article Image

'Dare Mighty Things'

We the people need to take more control of how we move into the brave new worlds beyond our planet.

By Kara Swisher

Article Image

Operation Car Wash Was No Magic Bullet

The largest anti-graft effort in the world couldn't stop endemic corruption in Brazil.

By Gaspard Estrada

Article Image

Forward this newsletter to friends to share ideas and perspectives that will help inform their lives. They can sign up here. Do you have feedback? Email us at opiniontoday@nytimes.com

Contact Us
If you have questions about your Times account, delivery problems or other issues, visit our Help Page or contact The Times.

Need help? Review our newsletter help page or contact us for assistance.

David Leonhardt's newsletter is now the Opinion Today newsletter. You received this email because you signed up for David Leonhardt's newsletter or the Opinion Today newsletter from The New York Times.

To stop receiving these emails, unsubscribe or manage your email preferences.

Subscribe to The Times

Connect with us on:

facebooktwitterinstagram

Change Your EmailPrivacy PolicyContact UsCalifornia Notices

The New York Times Company. 620 Eighth Avenue New York, NY 10018